Amicus Therapeutics Analyst Ratings
Amicus Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/09/2023 | 32.04% | Morgan Stanley | $14 → $15 | Maintains | Equal-Weight |
| 10/10/2023 | 23.24% | Morgan Stanley | $15 → $14 | Maintains | Equal-Weight |
| 09/29/2023 | 67.25% | JP Morgan | $17 → $19 | Maintains | Overweight |
| 07/11/2023 | 32.04% | Morgan Stanley | $15 → $15 | Reiterates | Equal-Weight → Equal-Weight |
| 03/28/2023 | 49.65% | B of A Securities | $16 → $17 | Maintains | Buy |
| 03/02/2023 | 49.65% | UBS | $15 → $17 | Maintains | Buy |
| 03/02/2023 | -3.17% | Goldman Sachs | $10 → $11 | Maintains | Neutral |
| 01/18/2023 | 40.85% | BTIG | $14 → $16 | Maintains | Buy |
| 11/08/2022 | 32.04% | Morgan Stanley | $14 → $15 | Maintains | Equal-Weight |
| 09/09/2022 | 23.24% | Morgan Stanley | → $14 | Initiates Coverage On | → Equal-Weight |
| 02/24/2022 | 23.24% | SVB Leerink | $16 → $14 | Maintains | Outperform |
| 01/14/2022 | 40.85% | SVB Leerink | $12 → $16 | Upgrades | Market Perform → Outperform |
| 01/13/2022 | 32.04% | Cantor Fitzgerald | $16 → $15 | Maintains | Overweight |
| 11/15/2021 | 40.85% | Stifel | $12 → $16 | Upgrades | Hold → Buy |
| 09/30/2021 | 40.85% | JP Morgan | → $16 | Upgrades | Neutral → Overweight |
| 09/30/2021 | 5.63% | SVB Leerink | $13 → $12 | Maintains | Market Perform |
| 05/27/2021 | — | Needham | Initiates Coverage On | → Hold | |
| 05/21/2021 | 40.85% | UBS | → $16 | Initiates Coverage On | → Buy |
| 04/14/2021 | — | Cantor Fitzgerald | Upgrades | Neutral → Overweight | |
| 03/22/2021 | 14.44% | SVB Leerink | $15 → $13 | Maintains | Market Perform |
| 03/02/2021 | 14.44% | Stifel | → $13 | Initiates Coverage On | → Hold |
| 02/12/2021 | 49.65% | Cantor Fitzgerald | $30 → $17 | Downgrades | Overweight → Neutral |
| 02/12/2021 | 67.25% | JP Morgan | → $19 | Downgrades | Overweight → Neutral |
| 02/12/2021 | 32.04% | SVB Leerink | $30 → $15 | Downgrades | Outperform → Market Perform |
| 12/14/2020 | 164.08% | SVB Leerink | $24 → $30 | Maintains | Outperform |
| 11/11/2020 | 84.86% | Berenberg | → $21 | Initiates Coverage On | → Hold |
| 11/06/2020 | 111.27% | SVB Leerink | $19 → $24 | Maintains | Outperform |
| 08/11/2020 | 76.06% | Citigroup | $15 → $20 | Maintains | Buy |
| 06/17/2020 | 67.25% | BTIG | → $19 | Initiates Coverage On | → Buy |
| 02/04/2020 | 76.06% | Cantor Fitzgerald | $19 → $20 | Assumes | → Overweight |
| 04/05/2019 | — | Janney Montgomery Scott | Initiates Coverage On | → Buy | |
| 01/30/2019 | 76.06% | Cantor Fitzgerald | → $20 | Initiates Coverage On | → Overweight |
| 01/17/2019 | — | Citigroup | Upgrades | Neutral → Buy | |
| 12/18/2018 | 58.45% | Guggenheim | → $18 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/09/2023 | 32.04% | 摩根士丹利 | 14 美元 → 15 美元 | 维护 | 重量相等 |
| 2023 年 10 月 10 日 | 23.24% | 摩根士丹利 | 15 美元 → 14 美元 | 维护 | 重量相等 |
| 09/29/2023 | 67.25% | 摩根大通 | 17 美元 → 19 美元 | 维护 | 超重 |
| 07/11/2023 | 32.04% | 摩根士丹利 | 15 美元 → 15 美元 | 重申 | 等重 → 等重 |
| 03/28/2023 | 49.65% | B of A 类证券 | 16 美元 → 17 美元 | 维护 | 买 |
| 03/02/2023 | 49.65% | 瑞银（UBS） | 15 美元 → 17 美元 | 维护 | 买 |
| 03/02/2023 | -3.17% | 高盛 | 10 美元 → 11 美元 | 维护 | 中立 |
| 01/18/2023 | 40.85％ | BTIG | 14 美元 → 16 美元 | 维护 | 买 |
| 2022 年 8 月 11 日 | 32.04% | 摩根士丹利 | 14 美元 → 15 美元 | 维护 | 重量相等 |
| 09/09/2022 | 23.24% | 摩根士丹利 | → 14 美元 | 启动覆盖范围开启 | → 重量相等 |
| 2022 年 2 月 24 日 | 23.24% | SVB Leerink | 16 美元 → 14 美元 | 维护 | 跑赢大盘 |
| 2022 年 1 月 14 日 | 40.85％ | SVB Leerink | 12 美元 → 16 美元 | 升级 | 市场表现 → 跑赢大盘 |
| 01/13/2022 | 32.04% | 坎托·菲茨杰拉德 | 16 美元 → 15 美元 | 维护 | 超重 |
| 11/15/2021 | 40.85％ | Stifel | 12 美元 → 16 美元 | 升级 | 持有 → 买入 |
| 09/30/2021 | 40.85％ | 摩根大通 | → 16 美元 | 升级 | 中性 → 超重 |
| 09/30/2021 | 5.63% | SVB Leerink | 13 美元 → 12 美元 | 维护 | 市场表现 |
| 05/27/2021 | — | 尼德姆 | 启动覆盖范围开启 | → 按住 | |
| 05/21/2021 | 40.85％ | 瑞银（UBS） | → 16 美元 | 启动覆盖范围开启 | → 购买 |
| 2021 年 4 月 14 日 | — | 坎托·菲茨杰拉德 | 升级 | 中性 → 超重 | |
| 03/22/2021 | 14.44% | SVB Leerink | 15 美元 → 13 美元 | 维护 | 市场表现 |
| 2021 年 2 月 3 日 | 14.44% | Stifel | → 13 美元 | 启动覆盖范围开启 | → 按住 |
| 02/12/2021 | 49.65% | 坎托·菲茨杰拉德 | 30 美元 → 17 美元 | 降级 | 超重 → 中性 |
| 02/12/2021 | 67.25% | 摩根大通 | → 19 美元 | 降级 | 超重 → 中性 |
| 02/12/2021 | 32.04% | SVB Leerink | 30 美元 → 15 美元 | 降级 | 跑赢大盘 → 市场表现 |
| 2020 年 12 月 14 日 | 164.08% | SVB Leerink | 24 美元 → 30 美元 | 维护 | 跑赢大盘 |
| 11/11/2020 | 84.86% | 贝伦贝格 | → 21 美元 | 启动覆盖范围开启 | → 按住 |
| 11/06/2020 | 111.27% | SVB Leerink | 19 美元 → 24 美元 | 维护 | 跑赢大盘 |
| 08/11/2020 | 76.06% | 花旗集团 | 15 美元 → 20 美元 | 维护 | 买 |
| 2020 年 6 月 17 日 | 67.25% | BTIG | → 19 美元 | 启动覆盖范围开启 | → 购买 |
| 02/04/2020 | 76.06% | 坎托·菲茨杰拉德 | 19 美元 → 20 美元 | 假设 | → 超重 |
| 2019 年 5 月 4 日 | — | 詹尼蒙哥马利斯科特 | 启动覆盖范围开启 | → 购买 | |
| 01/30/2019 | 76.06% | 坎托·菲茨杰拉德 | → 20 美元 | 启动覆盖范围开启 | → 超重 |
| 01/17/2019 | — | 花旗集团 | 升级 | 中性 → 买入 | |
| 12/18/2018 | 58.45% | 古根海姆 | → 18 美元 | 启动覆盖范围开启 | → 购买 |
What is the target price for Amicus Therapeutics (FOLD)?
Amicus Therapeutics（FOLD）的目标价格是多少？
The latest price target for Amicus Therapeutics (NASDAQ: FOLD) was reported by Morgan Stanley on November 9, 2023. The analyst firm set a price target for $15.00 expecting FOLD to rise to within 12 months (a possible 32.04% upside). 8 analyst firms have reported ratings in the last year.
摩根士丹利于2023年11月9日公布了Amicus Therapeutics（纳斯达克股票代码：FOLD）的最新目标股价。该分析公司将目标股价定为15.00美元，预计FOLD将在12个月内升至12个月内（可能上涨32.04％）。去年有8家分析公司公布了评级。
What is the most recent analyst rating for Amicus Therapeutics (FOLD)?
Amicus Therapeutics（FOLD）的最新分析师评级是多少？
The latest analyst rating for Amicus Therapeutics (NASDAQ: FOLD) was provided by Morgan Stanley, and Amicus Therapeutics maintained their equal-weight rating.
Amicus Therapeutics（纳斯达克股票代码：FOLD）的最新分析师评级由摩根士丹利提供，Amicus Therapeutics维持同等权重评级。
When is the next analyst rating going to be posted or updated for Amicus Therapeutics (FOLD)?
Amicus Therapeutics（FOLD）的下一份分析师评级何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amicus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amicus Therapeutics was filed on November 9, 2023 so you should expect the next rating to be made available sometime around November 9, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Amicus Therapeutics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Amicus Therapeutics的最新评级是在2023年11月9日公布的，因此您应该预计下一个评级将在2024年11月9日左右公布。
Is the Analyst Rating Amicus Therapeutics (FOLD) correct?
分析师对Amicus Therapeutics（FOLD）的评级正确吗
While ratings are subjective and will change, the latest Amicus Therapeutics (FOLD) rating was a maintained with a price target of $14.00 to $15.00. The current price Amicus Therapeutics (FOLD) is trading at is $11.36, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Amicus Therapeutics（FOLD）评级保持不变，目标股价为14.00美元至15.00美元。Amicus Therapeutics（FOLD）目前的交易价格为11.36美元，超出了分析师的预期区间。